Translational research in neurology and neuroscience 2010: Multiple sclerosis

Olaf Stüve, Bernd C. Kieseier, Bernhard Hemmer, Hans Peter Hartung, Amer Awad, Elliot M. Frohman, Benjamin M. Greenberg, Michael K. Racke, Scott S. Zamvil, J. Theodore Phillips, Ralf Gold, Andrew Chan, Uwe Zettl, Ron Milo, Ellen Marder, Omar Khan, Todd N. Eagar

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.

Original languageEnglish (US)
Pages (from-to)1307-1315
Number of pages9
JournalArchives of neurology
Issue number11
StatePublished - Nov 2010

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Translational research in neurology and neuroscience 2010: Multiple sclerosis'. Together they form a unique fingerprint.

Cite this